Obexelimab
- Generic Name
- Obexelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1690307-05-1
- Unique Ingredient Identifier
- RM16A4BA8R
- Background
Obexelimab is under investigation in clinical trial NCT02725515 (A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 93
- Registration Number
- NCT06564311
- Locations
- 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇨🇿Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia
🇺🇸Regina Berkovich MD PhD, Inc, West Hollywood, California, United States
A Study of Obexelimab in Patients with Systemic Lupus Erythematosus
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 190
- Registration Number
- NCT06559163
- Locations
- 🇧🇬
University Multiprofile Hospital for Active Treatment "Eurohospital Plovdiv", Plovdiv, Bulgaria
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath